dm+d

Unassigned

New Medicines

Graft versus host disease (GvHD), steroid-resistant, gastrointestinal-predominant

Information

Microbiome biotherapeutic
MaaT Pharma
MaaT Pharma

Development and Regulatory status

Phase II Clinical Trials
Phase III Clinical Trials
Phase II Clinical Trials
Yes
Yes

Category

Standardized, pooled-donor, high-richness microbiome biotherapeutic
GvHD can occur after hematopoietic stem cell transplantation, a therapy for many hematological malignancies. GI aGvHD develops in around 50% due to the transplanted immune cells attacking the patient’s tissues and results in diarrhoea, vomiting pain and mucosal ulceration and bleeding leading to high patient morbidity and mortality [1,2].
Graft versus host disease (GvHD), steroid-resistant, gastrointestinal-predominant
Rectal